Bluebird Bio

Health biotech drug development genetics oncology

Bluebird Bio is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. The Company's clinical programs in severe genetic diseases include our LentiGlobin product candidate to treat transfusion dependent β-thalassemia and to treat severe sickle cell disease and itsLenti-D product candidate to treat cerebral adrenoleukodystrophy. Bluebird Bio programs in oncology are built upon its leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor and T cell receptor T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. The Company also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across its pipeline.

Revenue(FY, 2017)

$35.4 M

Market capitalization(2018-06-14)

$9.9 B

Type

Public

Cambridge, US

Founded

1992

Size (employees)

418 (est)+24%

Website

bluebirdbio.com

Bluebird Bio was founded in 1992 and is headquartered in Cambridge, US

Report incorrect company information

Key People/Management at Bluebird Bio

Nick Leschly

CEO

Jeffrey Walsh

COO

Report incorrect company information

Bluebird Bio Office Locations

Bluebird Bio has offices in Zug, Cambridge and Seattle

Cambridge, US (HQ)

60 Binney St.

Seattle, US

208 1616 Eastlake Ave E

Zug, CH

135 Baarerstrasse

Show all (3)

Report incorrect company information

Bluebird Bio Financials and Metrics

Bluebird Bio Financials

Bluebird Bio's revenue was reported to be $35.43 m in FY, 2017

Summary

USD
Revenue (Q1, 2018)	16 m
Net income (Q1, 2018)	(115.1 m)
EBIT (Q1, 2018)	(116.6 m)
Market capitalization (14-Jun-2018)	9.9 b
Closing share price (14-Jun-2018)	197
Cash (31-Mar-2018)	456.5 m

Bluebird Bio's current market capitalization is $9.9 b.

Income Statement

Annual

USD	FY, 2013	Y, 2014	Y, 2015	FY, 2016	FY, 2017
Revenue	20.2 m	25.4 m	14.1 m	6.2 m	35.4 m
Revenue growth, %		26%	(45%)	(56%)
General and administrative expense				65.1 m	93.6 m
R&D expense				204.8 m	273 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Revenue	6.4 m	6.3 m	6.3 m	6.4 m	6.3 m	4.9 m	1.3 m	1.5 m	1.6 m	1.6 m	6.8 m	16.7 m	7.7 m	16 m
General and administrative expense	3.8 m	5.5 m	5.7 m	6.6 m	7.3 m	10.7 m	13.7 m	16 m	18.4 m	14.6 m	20.3 m	21.2 m	23 m	34.9 m
R&D expense	8.7 m	11.5 m	13.9 m	16.6 m	23.7 m	44.3 m	30.4 m	41.9 m	41.8 m	64 m	55 m	64.3 m	61.5 m	97.1 m
Operating expense total	12.5 m	17 m	19.7 m	23.4 m	31.3 m	57 m	44.5 m	58.9 m	61.5 m	79.7 m	76.7 m	84.5 m	85.4 m	132.6 m

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	206.3 m	347.8 m	164.3 m	278.9 m	758.5 m
Accounts Receivable
Inventories	5 m	4.5 m	6 m	19.8 m
Current Assets	212 m	480 m	524 m	724.2 m	1.3 b

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Cash	216.8 m	192.5 m	175.7 m	89.6 m	133.2 m	593.3 m	417.5 m	192.6 m	222.6 m	245.2 m	216 m	686.3 m	238 m	456.5 m
Current Assets	221.5 m	195.9 m	182.9 m	223.3 m	340.8 m	815.5 m	713.2 m	561 m	582.9 m	608.8 m	667.3 m	1.1 b	758.7 m	1.2 b
PP&E	5.4 m	12 m	12.9 m	15 m	16.9 m	16.8 m	61.6 m	96.6 m	109.3 m	131.7 m	181.7 m	180.4 m	182.4 m	204.2 m
Goodwill			13.1 m	13.1 m	13.1 m	13.1 m	13.1 m	13.1 m	13.1 m	13.1 m	13.1 m	13.1 m	13.1 m	13.1 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(25.3 m)	(48.7 m)	(166.8 m)	(263.5 m)	(335.6 m)
Depreciation and Amortization	941 k	4.2 m	7.4 m	9.6 m	13.5 m
Inventories				(14 m)
Accounts Payable	2.1 m	(2.2 m)	2.5 m	6.7 m	526 k

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income	(17.2 m)	(10.6 m)	(1.5 m)	(17 m)	(24.8 m)	(51.8 m)	(42.9 m)	(56.3 m)	(58.8 m)	(77 m)	(68.7 m)	(115.1 m)
Depreciation and Amortization	610 k											4 m
Accounts Payable	(1 m)		2.6 m	3.6 m	2.6 m	2.3 m	3.5 m	3.1 m	2.4 m	6.7 m	8.8 m	(737 k)
Cash From Operating Activities	48.9 m											(108.8 m)